---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-150894"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T14:48:04.520981+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galera Q1 net loss $15.4M; plans avasopasem NDA by end 2022

## Summary
- Net loss $(15.4M) ($0.58/share) vs $(18.7M) ($0.75) in Q1 2021; cash $60.9M funds into H2 2023.
- Plans to submit NDA for avasopasem for severe oral mucositis by end of 2022 after FDA discussions.
- Phase 3 ROMAN data accepted for oral presentation at 2022 ASCO; positive Phase 2a AESOP data reported.
- R&D expenses $8.1M (down from $12.4M); G&A expenses $5.0M (flat).
- Enrollment ongoing in Phase 2b GRECO-2 trial of rucosopasem for pancreatic cancer and Phase 1/2 GRECO-1 for NSCLC.

## SEC filing metadata
- accession: 0001193125-22-150894
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312522150894/0001193125-22-150894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312522150894/d277547d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-150894
- JSON: https://secwatch.observer/filing/0001193125-22-150894.json
- Plain text: https://secwatch.observer/filing/0001193125-22-150894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.